Valneva

Crucell Sweden specializes in contract manufacturing services primarily for vaccine companies, both domestically and internationally. The company is involved in the development, manufacturing, marketing, and distribution of vaccines, producing biological bulk and finished products for clinical trials and market supply. Additionally, Crucell Sweden focuses on developing antibodies aimed at preventing and treating infectious diseases, contributing to the advancement of public health through its comprehensive capabilities in the vaccine sector.

BliNK Biomedical SAS is a biotechnology company based in Lyon, France, founded in 2014. The company specializes in the discovery and development of monoclonal antibodies aimed at treating life-threatening diseases, particularly in the field of immuno-oncology. Its lead program focuses on a monoclonal antibody that targets an immune checkpoint, enhancing the body's immune response against tumors. BliNK Biomedical employs a unique B cell technology platform that facilitates the selection and isolation of specific antibody-producing cells from various species, including humans and animals. This innovative approach allows researchers to efficiently identify and develop next-generation anti-tumor therapeutics targeting novel immuno-oncology and immune-checkpoint pathways.